Bio-tecnología 3D. Future is now

[Robopoli]

Hay alguién dentro?
Sigue la jodía pegando unos vaivenes que para qué aunque mientras siga la tendencia que tiene no pienso quejarme

 

[SPK]

Yo sigo pero llevaba muy poco.Si bajara de 4.5,riesgo de quiebra etc vendería,si no a esperar un x10

 

[Robopoli]

Es como para intentar aguantarlas este año.
Pinta muy bien pero ya veremos que es más fuerte si el miedo o la codicia

 

[Robopoli]

Buenas noticias! En pre-market +17,45% de momento. Veremos donde llega!

Organovo Holdings Inc : Organovo Announces First Delivery of 3D Liver Tissue to Key Opinion Leader | 4-Traders

 

[Chila]

Enhorabuena Robopoli.
TE he enviado un privado y ahora veo este hilo.
¿véis futuro?

 

[Ladrillófilo]

Este tipo argumenta que la mejor idea de cortos en 2014 es ONVO. Estoy dentro amasando unas generosas pérdidas.

Organovo Holdings Inc (ONVO) news: Best Short Idea In 2014: Organovo Holdings, Inc. - Seeking Alpha

Summary

ONVO's promise of creating "3d bio-printed organs" for humans is a pipe dream decades away, and ONVO has neither the capital nor people necessary to succeed at such a venture.
ONVO's 3D bioprinting technology is far too slow and expensive to deliver a viable product for drug toxicity testing, the only near-term market identified by management.
ONVO's patent protection is extremely weak and does not come close to claiming all of the methods necessary to "print" human organs in the future.
ONVO scientific co-founder, Gabor Forgacs, has left his role at the company and is pursuing more viable opportunities (synthetic leather & meat) with notable venture capital backers.
ONVO executives are cashing out: the top three (Keith Murphy, Barry Michaels and Sharon Presnell) have sold ~$7 million worth of ONVO stock and pay themselves nearly $1 million annually.
[Editor's Note: Some facts have been corrected in this article after we were contacted by Organovo's management]

I am writing this solely to demonstrate high quality trade ideas for my investment firm, Valkyrie Capital. In doing so, I am putting my personal reputation (and that of my firm) on the line. I am not a serial short seller and ONVO had originally been brought to me as a long idea, but after some research, it has become my top short idea for 2014. While I am short, I am not looking to deliberately "short and distort" either: my position is based on detailed research, my own deductions and an expectation that Organovo's share price will decline significantly before December 2014. It's also worth noting I do not post frequently and my last post recommended long positions in Two Harbors (TWO) LEAPs and levered Annaly Capital (NLY) preferred stock on December 16th, which are both up more than 50% and 18% - 25%, respectively.

 

[Robopoli]

Este tipo argumenta que la mejor idea de cortos en 2014 es ONVO. Estoy dentro amasando unas generosas pérdidas.

Organovo Holdings Inc (ONVO) news: Best Short Idea In 2014: Organovo Holdings, Inc. - Seeking Alpha

Summary

ONVO's promise of creating "3d bio-printed organs" for humans is a pipe dream decades away, and ONVO has neither the capital nor people necessary to succeed at such a venture.
ONVO's 3D bioprinting technology is far too slow and expensive to deliver a viable product for drug toxicity testing, the only near-term market identified by management.
ONVO's patent protection is extremely weak and does not come close to claiming all of the methods necessary to "print" human organs in the future.
ONVO scientific co-founder, Gabor Forgacs, has left his role at the company and is pursuing more viable opportunities (synthetic leather & meat) with notable venture capital backers.
ONVO executives are cashing out: the top three (Keith Murphy, Barry Michaels and Sharon Presnell) have sold ~$7 million worth of ONVO stock and pay themselves nearly $1 million annually.
[Editor's Note: Some facts have been corrected in this article after we were contacted by Organovo's management]

I am writing this solely to demonstrate high quality trade ideas for my investment firm, Valkyrie Capital. In doing so, I am putting my personal reputation (and that of my firm) on the line. I am not a serial short seller and ONVO had originally been brought to me as a long idea, but after some research, it has become my top short idea for 2014. While I am short, I am not looking to deliberately "short and distort" either: my position is based on detailed research, my own deductions and an expectation that Organovo's share price will decline significantly before December 2014. It's also worth noting I do not post frequently and my last post recommended long positions in Two Harbors (TWO) LEAPs and levered Annaly Capital (NLY) preferred stock on December 16th, which are both up more than 50% and 18% - 25%, respectively.

Yo me salí sacando algo de plusvis pera nada superestelar al final (un 10% o algo así).
Cada vez tengo más claro que con este tipo de valores lo mejor no es el buy & hold de toda la vida. Por eso pedía arriba alguna plantilla de GAD/AIM. Para hacer un poco de backtesting y ver si se puede optimizar un poco el tema con tecnológicas, biotech y similares.

 

[todoayen]

"Cada vez tengo más claro que con este tipo de valores lo mejor no es el buy & hold de toda la vida. Por eso pedía arriba alguna plantilla de GAD/AIM. Para hacer un poco de backtesting y ver si se puede optimizar un poco el tema con tecnológicas, biotech y similares."

¿Veis como los mercados somos todos y en la bolsa entra cualquiera?

¿Quién no tiene por algún cajón una plantilla de GAD/AIM y mientras está cagando se entretiene haciendo un poco de backtesting?

 

[SPK]

Este tipo argumenta que la mejor idea de cortos en 2014 es ONVO. Estoy dentro amasando unas generosas pérdidas.

Organovo Holdings Inc (ONVO) news: Best Short Idea In 2014: Organovo Holdings, Inc. - Seeking Alpha

Summary

ONVO's promise of creating "3d bio-printed organs" for humans is a pipe dream decades away, and ONVO has neither the capital nor people necessary to succeed at such a venture.
ONVO's 3D bioprinting technology is far too slow and expensive to deliver a viable product for drug toxicity testing, the only near-term market identified by management.
ONVO's patent protection is extremely weak and does not come close to claiming all of the methods necessary to "print" human organs in the future.
ONVO scientific co-founder, Gabor Forgacs, has left his role at the company and is pursuing more viable opportunities (synthetic leather & meat) with notable venture capital backers.
ONVO executives are cashing out: the top three (Keith Murphy, Barry Michaels and Sharon Presnell) have sold ~$7 million worth of ONVO stock and pay themselves nearly $1 million annually.
[Editor's Note: Some facts have been corrected in this article after we were contacted by Organovo's management]

I am writing this solely to demonstrate high quality trade ideas for my investment firm, Valkyrie Capital. In doing so, I am putting my personal reputation (and that of my firm) on the line. I am not a serial short seller and ONVO had originally been brought to me as a long idea, but after some research, it has become my top short idea for 2014. While I am short, I am not looking to deliberately "short and distort" either: my position is based on detailed research, my own deductions and an expectation that Organovo's share price will decline significantly before December 2014. It's also worth noting I do not post frequently and my last post recommended long positions in Two Harbors (TWO) LEAPs and levered Annaly Capital (NLY) preferred stock on December 16th, which are both up more than 50% and 18% - 25%, respectively.

Yo por artículos como este me acojoné y acabé vendiendo perdiendo un 10% .Vaya rachita que llevo :ouch: